Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

AB-101 as Monotherapy and In Combination With Rituximab in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04673617
Recruitment Status : Recruiting
First Posted : December 17, 2020
Last Update Posted : April 1, 2021
Sponsor:
Information provided by (Responsible Party):
Artiva Biotherapeutics, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : June 2023